• Bsa I (RNase-free): Practical DNA Cleavage Guide

  2026-08-31

  Bsa I (RNase-free) provides sequence-directed DNA cleavage for gene cloning, DNA manipulation, and other molecular biology research workflows where RNA contamination must be minimized. It is intended for controlled scientific research only and should not be used for diagnostic, clinical, or medical applications.

• RRP Restores Lipid Metabolism in HIRI

  2026-08-30

  The reference study shows that Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury by correcting hepatocyte cholesterol handling rather than acting only as general antioxidants. Its mechanistic model connects AMPK activation and mTOR suppression with reduced SCAP–SREBP2 cholesterol synthesis and enhanced LXRα-dependent cholesterol efflux, providing a useful framework for lipid-focused liver injury research.

• Palonosetron in Chemotherapy-Induced Nausea

  2026-08-29

  The reference article by Ruhlmann and Herrstedt evaluates palonosetron as a long-acting 5-HT3 receptor antagonist and places its pharmacology in the context of clinical chemotherapy-induced nausea and vomiting prevention. Its main practical contribution is a cautious translation of receptor affinity, allosteric binding, and prolonged activity into evidence about acute and delayed emesis control, tolerability, and combination antiemetic strategies.

• Sulfo-Cy5 NHS Ester for Aqueous Immune Imaging

  2026-08-28

  Sulfo-Cy5 NHS ester enables far-red labeling of amine-containing proteins in aqueous workflows, helping protect solvent-sensitive biomolecules while supporting quantitative cellular imaging. Its sulfonated design, high extinction coefficient, and compatibility with VLA-4 tracking make it a practical bridge between protein conjugation and immune-cell uptake assays.

• Thiothixene: From Dopamine Antagonism to Efferocytosis

  2026-08-28

  Thiothixene is best understood not only as a typical antipsychotic agent, but also as a mechanistically distinctive probe for macrophage efferocytosis. This article connects dopamine receptor pharmacology, vitamin A signaling, assay design, pharmacokinetics, and translational strategy while defining the boundaries between preclinical macrophage findings and schizophrenia treatment.

• EZ Cap™ Firefly Luciferase mRNA Workflow

  2026-08-28

  Build more consistent reporter experiments with a Cap1- and poly(A)-optimized transcript designed for strong, sustained firefly luciferase expression. This workflow connects routine cell-based translation studies with gene regulation assays and carefully qualified in vivo bioluminescence imaging.

• Keap1–Nrf2 Inhibition Suppresses AD Ferroptosis

  2026-08-27

  The reference study identifies compound 4–95 as a selective Keap1–Nrf2 protein–protein interaction inhibitor that protects neuronal models from ferroptosis and improves cognitive outcomes in an amyloid-driven mouse model. Its key contribution is mechanistic linkage of Nrf2 activation to the GPX4/SLC7A11 anti-ferroptotic axis, reduced amyloid and pathological Tau signals, and improved memory-related behavior.

• NU7441 (KU-57788) DNA-PK Workflow Guide

  2026-08-26

  NU7441 (KU-57788) provides a selective way to test how DNA-PK inhibition reshapes DNA damage responses, cell-cycle behavior, and sensitivity to etoposide. This guide connects practical oncology workflows with an exploratory TDP-43 assay strategy inspired by recent cytosolic-DNA research.

• Eltanexor: XPO1 Workflows for Cancer Research

  2026-08-26

  Eltanexor (KPT-8602) gives researchers a practical way to connect XPO1 inhibition with apoptosis, nuclear protein retention, and Wnt/β-catenin signaling. This guide translates hematologic cancer evidence and a colorectal cancer chemoprevention study into reproducible cell, organoid, and in vivo workflows.

• PF-562271 HCl: A Perturbation-Aware Cancer Research Guide

  2026-08-26

  Explore PF-562271 HCl as a FAK/Pyk2 inhibitor for linking kinase perturbation with multimodal tumor-response biology. This guide translates radiopathomics findings into practical assay and experimental design decisions for cancer research.

• Cy3-UTP Workflow for Kinetic RNA Studies

  2026-08-25

  Cy3-UTP enables bright, photostable RNA labeling for in vitro transcription, imaging, interaction studies, and detection assays. This workflow connects practical labeling control with stopped-flow strategies for resolving fast RNA conformational changes.

• In Vitro Drug Responses: Viability, Killing, and Timing

  2026-08-24

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. By separating growth inhibition from cell killing and considering their relative timing, the study provides a more precise framework for interpreting in vitro pharmacology and designing follow-up experiments.

• Genotyping Kit for target alleles: faster PCR

  2026-08-24

  Accelerate allele screening across insect, tissue, fish, and cell samples with single-tube DNA preparation and direct gel-ready PCR. This workflow connects practical colony genotyping with mechanistic studies such as E-cadherin regulation in experimental colitis.

• DOPE in Lipid Design: From Fusion to Assay Logic

  2026-08-23

  1,2-Dioleoyl-sn-glycero-3-PE (DOPE) is best understood as a context-dependent membrane-engineering lipid, not merely a transfection additive. This article connects its endosomal-fusion role with phospholipid-centered assay design and clarifies what rice blast lipidomics can—and cannot—tell delivery researchers.

• Mitomycin C Workflows for Cancer Research

  2026-08-22

  Build more informative cancer assays with Mitomycin C by pairing DNA damage, proliferation, and apoptosis readouts rather than relying on viability alone. This workflow also shows how target-specific controls from antiviral genome-editing research can strengthen mechanistic interpretation of combination studies.

449 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page